Shares in Teva Pharmaceuticals (NYSE:TEVA) fell today after the pharmaceutical company missed sales expectations on Wall Street with its fourth quarter results.
The Israel-based company posted a net loss of -$11.6 billion, or -$11.43 per share, on sales of $5.46 billion for the 3 months ended Dec. 31, for a sales loss of -16% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva shares tumble after “challenging” Q4, FY17 appeared first on MassDevice.